Cover Image
市場調查報告書

性傳染病(STD)檢驗的全球市場(對像病種·檢驗地方·設備·各地區) - 市場規模,佔有率,全球趨勢,企業簡介,需求,考察,分析,調查,報告,機會,市場區隔及預測

Global Sexually Transmitted Diseases (STDs) Testing Market (Disease Types, Testing Volume, Testing Devices and Geography) - Industry Analysis and Forecast, 2013 - 2020

出版商 Allied Market Research 商品編碼 320860
出版日期 內容資訊 英文 110 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
性傳染病(STD)檢驗的全球市場(對像病種·檢驗地方·設備·各地區) - 市場規模,佔有率,全球趨勢,企業簡介,需求,考察,分析,調查,報告,機會,市場區隔及預測 Global Sexually Transmitted Diseases (STDs) Testing Market (Disease Types, Testing Volume, Testing Devices and Geography) - Industry Analysis and Forecast, 2013 - 2020
出版日期: 2014年11月14日 內容資訊: 英文 110 Pages
簡介

被稱為性病的性傳染病有增加的傾向,其診斷檢驗市場全球整體預測在2014年以後將以8.5%的年複合成長率擴大,並在2020年達到1674億美金的規模。

本報告以性傳染病(STD)檢驗的全球市場為焦點,依對象病種,檢驗地方,設備,地區別分析·預測供需規模的轉變,更彙整市場發展的推動·阻礙因素,診斷技術開發,競爭環境,主要加入企業等相關的最新資訊。

第1章 簡介

  • 報告內容
  • 調查實施的理由
  • 報告的主要優點
  • 主要市場區隔
  • 報告的推薦用戶層
  • 調查方法
    • 二次資訊調查
    • 一次資訊採訪
    • 分析工具及模式

第2章 摘要整理

  • 經營首腦的觀點
  • 市場預測(單位:100萬美元)
    • 穩定成長方案
    • 急速成長方案
    • 減速成長方案

第3章 市場概要

  • 市場定義和範圍
  • 性病診斷測試市場未來趨勢
  • 性病診斷測試市場技術的進步
  • 投資者盈利評價標準的新興國家
  • 重要發現
    • 性病診斷測試市場的重要影響係數
    • 性病診斷測試市場有力資金來源
    • 對性病診斷測試市場上成功的重要策略
  • 行政府法規和報酬制度
  • 價值鏈分析
  • 市場佔有率分析
  • 市場動態
    • 推動要素
    • 阻礙因素
    • 機會

第4章 性病診斷測試的全球市場 - 病類別

  • 披衣菌感染檢驗(數量及金額)
  • 一期及二期梅毒檢驗(數量及金額)
  • 淋病檢驗(數量及金額)
  • 單純皰疹病毒(HSV)檢驗(數量及金額)
  • 人類乳突病毒(HPV)檢驗(數量及金額)
  • 人類免疫缺陷病毒(HIV)檢驗(數量及金額)
  • 軟性下疳檢驗(數量及金額)

第5章 性病診斷測試的全球市場 - 檢驗地方

  • 研究設施檢驗
    • 重要市場趨勢
    • 重要成長係數及機會
    • 商業研究設施檢驗
    • 民間研究設施檢驗
    • 公共研究設施檢驗
  • 照護現場(POC)檢驗
    • 重要市場趨勢
    • 重要成長係數及機會

第6章 性病診斷測試的全球市場 - 檢驗設備別

  • 研究設施檢驗設備
    • PCR(聚合酵素鏈鎖反應)設備
    • 免疫層析法毛細管流動測試紙技術(分析設備·樣品)
    • 流式細胞儀
    • 光散射分析檢測設備
    • 酵素免疫分析法(ELISA)設備
  • 照護現場(POC)檢驗設備
    • Phone chips(微流體工程 + 資訊通訊技術)
    • 可攜式,桌上型,簡易診斷套件

第7章 性病診斷測試的全球市場 - 各地區

  • 北美
    • 重要市場趨勢
    • 競爭情形
    • 重要成長係數及機會
  • 歐洲
  • 亞太地區
  • 其他地區

第8章 企業簡介(企業概要,短評,收益,策略性動向及發展,SWOT分析)

  • Roche Diagnostics
  • BioMerieux
  • Hologic, Inc.
  • Becton Dickinson & Company
  • Cepheid, Inc.
  • Danaher Corporation
  • Affymetrix, Inc.
  • Alere, Inc.
  • Abbott Laboratories
  • DiaSorin
目錄
Product Code: ME 14385

Sexually Transmitted Diseases (STDs) are also known as Venereal diseases (VDs) or Sexually Transmitted Infections (STIs). A variety of methods have been employed for diagnosis of STDs that differ based on the type of disease. The objective of this report is to provide an in-depth understanding of diagnostic tests of STDs. The market diagnostic testing of STDs was valued at $96.7 billion in 2013 with a corresponding test volume of 4,204 million. Rising incidences of fatal STDs, corresponding high-economic burden and consequent implementation of Provider-Initiated Counselling and Testing (PICT) and Client-Initiated Counselling and Testing (CICT) drive the growth of STD testing market; however, inadequate infrastructure provisions such as labs, equipment and supplies, lack of trained laboratory personnel in the secluded geographic locations (for example, West African countries) and stigma associated with voluntary testing are likely to be the major restraints of the market. However, global initiatives along with development in healthcare infrastructure will provide future growth thrust for the market. Thus, the diagnostic testing of STDs is estimated to grow at a CAGR of 8.5% over the forecast period 2014-2020 to reach market size of $167.4 billion in 2020. The test volume will rise to 5,520 million in 2020.

The global market for diagnostic testing of STDs is segmented based on types of STDs - Chlamydia testing, Gonorrhoea testing, Syphilis testing, Human Immunodeficiency Virus (HIV) testing, Herpes Simplex Virus (HSV) testing, Human Papilloma Virus (HPV) testing and Chancroid testing. HIV testing, which is the third largest STD testing market, would grow at a CAGR of 10.9% during 2014 - 2020.

Based on point of testing, market is segmented in to laboratories and point-of-care (PoC). Currently, laboratories perform bulk of the tests and would continue to hold larger share of the market, both in terms of volume and revenue. PoCs will grow at constant rate during the forecast period.

The report also provides market size and forecast for testing devices used for carrying such tests. The market for STD testing devices was valued at $7.7 billion in 2013 with laboratory testing devices accounted for the most of the market and PoC devices shall grow at fastest rate.

As elaborated earlier, many healthcare institutions provide diagnostic testing services for STDs, such as specialized STD clinics, Genito-Urinary Medicine (GUM) clinics along with general hospitals, government laboratories and private diagnostic centres. The afore-mentioned thus constitute key market participants of the global diagnostic testing of STDs market. Along with the testing service providers, many companies provide devices such as laboratory instruments and POC testing kits/devices for STDs; for instance, Roche Holdings AG. Roche Holdings AG recently announced an immunoassay diagnostic test for the detection of Syphilis during a routine clinical practice. Other companies profiled in the report are BioMerieux, Hologic Inc., Becton Dickinson & Company, Cepheid Inc., Danaher Corporation, Affymetrix, Alere Inc., Abbott Laboratories, Bio-Rad Laboratories Inc., and DiaSorin.

KEY BENEFITS

  • The analysis helps in understanding the strategies adopted by various companies for gaining market share in the market for diagnostic testing of STDs
  • The report provides comprehensive analysis of factors that drive and restrict the growth of the market for diagnostic testing of STDs.
  • Market conditions of STD diagnostic testing market across all geographic regions are comprehensively analyzed. Key trends such as national and voluntary screening programs within regional markets, for example, European markets are expected to drive growth of the market.
  • Prime focus of the report is opportunity-analysis within this market. STD infected individuals refrain from testing in specialized STD clinics and Genito-Urinary Medicine (GUM) clinics due to the associated social stigma. Such change in the consumer buying behavior would prove to be an opportunity and be beneficial for public and private labs.

MARKET SEGMENTATION

The diagnostic testing of STDs market is segmented into types of STDs tested, testing devices, laboratory testing, PoC testing and geography.

MARKET BY SEXUALLY TRANSMITTED DISEASE TYPES

  • Chlamydia testing
  • Syphilis testing
  • Gonorrhoea testing
  • Herpes Simplex Virus testing
  • Human Papilloma Virus testing
  • Human Immunodeficiency Virus testing
  • Chancroid testing

MARKET BY LOCATION OF TESTING

  • Laboratory Testing
    • Commercial/Private labs
    • Public Health Labs
  • Point of Care (PoC) testing

MARKET BY TESTING DEVICES

  • Laboratory Devices: Instruments and systems
    • Thermal Cyclers - PCR
    • Lateral Flow Readers - Immunochromatographic assays
    • Flow Cytometers
    • Differential Light Scattering machines
    • Absorbance microplate reader - Enzyme Linked Immunosorbent Assay (ELISA)
  • POC testing Devices: Various diagnostic kits
    • Phone chips (microfluidics + ICT)
    • Portable / bench top / rapid diagnostic kits

MARKET BY GEOGRAPHY

  • North America
  • Europe
  • Asia-Pacific
  • Latin America, Middle East, Africa (LAMEA)

Table of Contents

1. INTRODUCTION

  • 1.1. Report Description
  • 1.2. Reason for doing the study
  • 1.3. Key Benefits
  • 1.4. Key Market Segments
  • 1.5. Key Audiences
  • 1.6. Research Methodology
    • 1.6.1. Secondary Research
    • 1.6.2. Primary Research
    • 1.6.3. Analyst tools and models

2. EXECUTIVE SUMMARY

  • 2.1. CXO perspective
  • 2.2. Market beyond what to expect by 2025($ Million)
    • 2.2.1. Moderate growth scenario
    • 2.2.2. Rapid growth scenario
    • 2.2.3. Diminishing growth scenario

3. MARKET OVERVIEW

  • 3.1. Market Definition and Scope
  • 3.2. Upcoming trends for venereal diseases diagnostic testing market
  • 3.3. Technological Advancements for venereal diseases diagnostic testing market
  • 3.4. Emerging economies as a beneficial criterion for the investors
  • 3.5. Key Findings
    • 3.5.1. Top Factors Impacting for venereal diseases diagnostic testing market
    • 3.5.2. Top Investment Pockets for venereal diseases diagnostic testing market
    • 3.5.3. Top winning strategies for venereal diseases diagnostic testing market
  • 3.6. Government Regulations and reimbursement
  • 3.7. Value chain analysis
  • 3.8. Market Share Analysis, 2013
  • 3.9. Market Dynamics
    • 3.9.1. Drivers
    • 3.9.2. Restraints
    • 3.9.3. Opportunities

4. GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET BY DISEASE TYPE

  • 4.1. Chlamydia testing (volume and value)
  • 4.2. P&S Syphilis testing (volume and value)
  • 4.3. Gonorrhea testing (volume and value)
  • 4.4. Herpes Simplex Virus (HSV) testing (volume and value)
  • 4.5. Human Papilloma Virus (HPV) testing (volume and value)
  • 4.6. Human Immunodeficiency Virus (HIV) testing (volume and value)
  • 4.7. Chancroid testing (volume and value)

5. GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET BY LOCATION OF TESTING

  • 5.1. Laboratory testing
    • 5.1.1. Key market trends
    • 5.1.2. Key growth factors and opportunities
    • 5.1.3. Market size and forecast
    • 5.1.4. Commercial laboratory testing
    • 5.1.5. Private laboratory testing
    • 5.1.6. Public laboratory testing
  • 5.2. POC testing
    • 5.2.1. Key market trends
    • 5.2.2. Key growth factors and opportunities
    • 5.2.3. Market size and forecast

6. GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET BY TESTING DEVICES

  • 6.1. Laboratory Testing Devices
    • 6.1.1. PCRs
    • 6.1.2. Immunochromatographic capillary flow dipstick technology (Assay)
    • 6.1.3. Flow Cytometers
    • 6.1.4. Differential Light Scattering
    • 6.1.5. Enzyme Linked Immunosorbent Assay (ELISA)
  • 6.2. POC Testing Devices
    • 6.2.1. Phone chips (microfluidics + ICT)
    • 6.2.2. Portable / bench top / rapid diagnostic kits

7. GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET BY GEOGRAPHY

  • 7.1. North America
    • 7.1.1. Key market trends
    • 7.1.2. Competitive scenario
    • 7.1.3. Key growth factors and opportunities
    • 7.1.4. Market size and forecast
  • 7.2. Europe
    • 7.2.1. Key market trends
    • 7.2.2. Competitive scenario
    • 7.2.3. Key growth factors and opportunities
    • 7.2.4. Market size and forecast
  • 7.3. Asia-Pacific
    • 7.3.1. Key market trends
    • 7.3.2. Competitive scenario
    • 7.3.3. Key growth factors and opportunities
    • 7.3.4. Market size and forecast
  • 7.4. LAMEA
    • 7.4.1. Key market trends
    • 7.4.2. Competitive scenario
    • 7.4.3. Key growth factors and opportunities
    • 7.4.4. Market size and forecast

8. COMPANY PROFILES

  • 8.1. Roche Diagnostics
    • 8.1.1. Overview
    • 8.1.2. Company snapshot
    • 8.1.3. Financial performance
    • 8.1.4. Strategic moves and developments
    • 8.1.5. SWOT analysis
  • 8.2. BioMerieux
    • 8.2.1. Overview
    • 8.2.2. Company snapshot
    • 8.2.3. Financial performance
    • 8.2.4. Strategic moves and developments
    • 8.2.5. SWOT analysis
  • 8.3. Hologic, Inc.
    • 8.3.1. Overview
    • 8.3.2. Company snapshot
    • 8.3.3. Financial performance
    • 8.3.4. Strategic moves and developments
    • 8.3.5. SWOT analysis
  • 8.4. Becton Dickinson & Company
    • 8.4.1. Overview
    • 8.4.2. Company snapshot
    • 8.4.3. Financial performance
    • 8.4.4. Strategic moves and developments
    • 8.4.5. SWOT analysis
  • 8.5. Cepheid, Inc.
    • 8.5.1. Overview
    • 8.5.2. Company snapshot
    • 8.5.3. Financial performance
    • 8.5.4. Strategic moves and developments
    • 8.5.5. SWOT analysis
  • 8.6. Danaher Corporation
    • 8.6.1. Overview
    • 8.6.2. Company snapshot
    • 8.6.3. Financial performance
    • 8.6.4. Strategic moves and developments
    • 8.6.5. SWOT analysis
  • 8.7. Affymetrix, Inc.
    • 8.7.1. Overview
    • 8.7.2. Company snapshot
    • 8.7.3. Financial performance
    • 8.7.4. Strategic moves and developments
    • 8.7.5. SWOT analysis
  • 8.8. Alere, Inc.
    • 8.8.1. Overview
    • 8.8.2. Company snapshot
    • 8.8.3. Financial performance
    • 8.8.4. Strategic moves and developments
    • 8.8.5. SWOT analysis
  • 8.9. Abbott Laboratories
    • 8.9.1. Overview
    • 8.9.2. Company snapshot
    • 8.9.3. Financial performance
    • 8.9.4. Strategic moves and developments
    • 8.9.5. SWOT analysis
  • 8.10. DiaSorin
    • 8.10.1. Overview
    • 8.10.2. Company snapshot
    • 8.10.3. Financial performance
    • 8.10.4. Strategic moves and developments
    • 8.10.5. SWOT analysis

List of Tables

  • TABLE 1: GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MODERATE GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
  • TABLE 2: GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MODERATE GROWTH SCENARIO MARKET VOLUME BY GEOGRAPHY, 2020-2025 (MILLION TESTS)
  • TABLE 3: GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING RAPID GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
  • TABLE 4: GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING RAPID GROWTH SCENARIO MARKET VOLUME BY GEOGRAPHY, 2020-2025 (MILLION TESTS)
  • TABLE 5: GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING DIMINISHING GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
  • TABLE 6: GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING DIMINISHING GROWTH SCENARIO MARKET VOLUME BY GEOGRAPHY, 2020-2025 (MILLION TESTS)
  • TABLE 7: GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET,REVENUE BY TYPES, 2013-2020 ($ MILLION)
  • TABLE 8: GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET, VOLUME BY TYPES, 2013-2020 (MILLION TESTS)
  • TABLE 9: GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET REVENUE BY GEOGRAPHY, 2013-2020, ($ MILLION)
  • TABLE 10: GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET VOLUME BY GEOGRAPHY, 2013-2020, (MILLION TESTS)
  • TABLE 11: GLOBAL CHLAMYDIA TESTING MARKET REVENUE BY GEOGRAPHY ($ MILLION)
  • TABLE 12: GLOBAL CHLAMYDIA TESTING MARKET VOLUME BY GEOGRAPHY (MILLION TESTS)
  • TABLE 13: GLOBAL P&S SYPHILIS TESTING MARKET REVENUE BY GEOGRAPHY ($ MILLION)
  • TABLE 14: GLOBAL P&S SYPHILIS TESTING MARKET VOLUME BY GEOGRAPHY(MILLION TESTS)
  • TABLE 15: GLOBAL GONORRHEA TESTING MARKET REVENUE BY GEOGRAPHY($ MILLION)
  • TABLE 16: GLOBAL GONORRHEA TESTING MARKET VOLUME BY GEOGRAPHY(MILLION TESTS)
  • TABLE 17: GLOBAL HERPES SIMPLEX VIRUS (HSV) TESTING MARKET REVENUE BY GEOGRAPHY ($ MILLION)
  • TABLE 18: GLOBAL HERPES SIMPLEX VIRUS (HSV) TESTING MARKET VOLUME BY GEOGRAPHY (MILLION TESTS)
  • TABLE 19: GLOBAL HUMAN PAPILLOMA VIRUS (HPV) TESTING MARKET REVENUE BY GEOGRAPHY ($ MILLION)
  • TABLE 20: GLOBAL HUMAN PAPILLOMA VIRUS (HPV) TESTING MARKET VOLUME BY GEOGRAPHY(MILLION TESTS)
  • TABLE 21: GLOBAL HUMAN IMMUNODEFICIENCY VIRUS (HIV) TESTING MARKET REVENUE BY GEOGRAPHY ($ MILLION)
  • TABLE 22: GLOBAL HUMAN IMMUNODEFICIENCY VIRUS (HIV) TESTING MARKET VOLUME BY GEOGRAPHY(MILLION TESTS)
  • TABLE 23: GLOBAL CHANCROID TESTING MARKET REVENUE BY GEOGRAPHY($ MILLION)
  • TABLE 24: GLOBAL CHANCROID TESTING MARKET VOLUME BY GEOGRAPHY(MILLION TESTS)
  • TABLE 25: GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET REVENUE BY LOCATION OF TESTING DEVICES, 2013-2020, ($ MILLION)
  • TABLE 26: GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET REVENUE BY LOCATION OF TESTING, 2013-2020, ($ MILLION TESTS)
  • TABLE 27: NORTH AMERICA VENEREAL DISEASES DIAGNOSTIC TESTING MARKET REVENUE, BY TYPES, 2013-2020 ($ MILLION)
  • TABLE 28: NORTH AMERICA VENEREAL DISEASES DIAGNOSTIC TESTING MARKET VOLUME, BY TYPES, 2013-2020 (MILLION TESTS)
  • TABLE 29: EUROPE VENEREAL DISEASES DIAGNOSTIC TESTING MARKET REVENUE, BY TYPES, 2013-2020 ($ MILLION TESTS)
  • TABLE 30: EUROPE VENEREAL DISEASES DIAGNOSTIC TESTING MARKET VOLUME, BY TYPES, 2013-2020 (MILLION TESTS)
  • TABLE 31: ASIA PACIFIC VENEREAL DISEASES DIAGNOSTIC TESTING MARKET REVENUE, BY TYPES, 2013-2020 ($ MILLION)
  • TABLE 32: ASIA PACIFIC VENEREAL DISEASES DIAGNOSTIC TESTING MARKET VOLUME, BY TYPES, 2013-2020 (MILLION TESTS)
  • TABLE 33: LAMEA VENEREAL DISEASES DIAGNOSTIC TESTING MARKET REVENUE, BY TYPES, 2013-2020 ($ MILLION)
  • TABLE 34: LAMEA VENEREAL DISEASES DIAGNOSTIC TESTING MARKET REVENUE, BY TYPES, 2013-2020 (MILLION TESTS)
  • TABLE 35: ROCHE DIAGNOSTICS BUSINESS SNAPSHOT
  • TABLE 36: BIOMERIEUX BUSINESS SNAPSHOT
  • TABLE 37: HOLOGIC, INC BUSINESS SNAPSHOT
  • TABLE 38: BECTON DICKINSON & COMPANY BUSINESS SNAPSHOT
  • TABLE 39: CEPHEID, INC.BUSINESS SNAPSHOT
  • TABLE 40: DANAHER CORPORATIONBUSINESS SNAPSHOT
  • TABLE 41: AFFYMETRIX, INC. BUSINESS SNAPSHOT
  • TABLE 42: ALERE, INC. BUSINESS SNAPSHOT
  • TABLE 43: ABBOTT LABORATORIES BUSINESS SNAPSHOT
  • TABLE 44: DIASORIN BUSINESS SNAPSHOT

List of Figures

  • FIG. 1: IMPACT ANALYSIS OF MODERATE GROWTH SCENARIO (2020-2025)
  • FIG. 2: IMPACT ANALYSIS OF RAPID GROWTH SCENARIO (2020-2025)
  • FIG. 3: IMPACT ANALYSIS OF DIMINISHING GROWTH SCENARIO (2020-2025)
  • FIG. 4: TOP FACTORS IMPACTING GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING (2014-2020) TOP WINNING STRATEGIES IN GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET
  • FIG. 5: TOP INVESTMENT POCKETS OF GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET
  • FIG. 6: PORTER'S FIVE FORCE MODEL OF GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET
  • FIG. 7: VALUE CHAIN ANALYSIS OF GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET
  • FIG. 8: ROCHE DIAGNOSTICS SWOT ANALYSIS
  • FIG. 9: BIOMERIEUX SWOT ANALYSIS
  • FIG. 10: HOLOGIC, INC SWOT ANALYSIS
  • FIG. 11: BECTON DICKINSON & COMPANY SWOT ANALYSIS
  • FIG. 12: CEPHEID, INC.BUSINESS SWOT ANALYSIS
  • FIG. 13: DANAHER CORPORATION SWOT ANALYSIS
  • FIG. 14: AFFYMETRIX, INC. SWOT ANALYSIS
  • FIG. 15: ALERE, INC. SWOT ANALYSIS
  • FIG. 16: ABBOTT LABORATORIES SWOT ANALYSIS
  • FIG. 17: DIASORIN SWOT ANALSIS
  • FIG. 18: BUSINESS PERFORMANCE OF ROCHE DIAGNOSTICS
  • FIG. 19: BUSINESS PERFORMANCE OF BIOMERIEUX
  • FIG. 20: BUSINESS PERFORMANCE OF HOLOGIC, INC
  • FIG. 21: BUSINESS PERFORMANCE OF BECTON DICKINSON & COMPANY
  • FIG. 22: BUSINESS PERFORMANCE OF CEPHEID, INC.
  • FIG. 23: BUSINESS PERFORMANCE OF DANAHER CORPORATION
  • FIG. 24: BUSINESS PERFORMANCE OF AFFYMETRIX, INC.
  • FIG. 25: BUSINESS PERFORMANCE OF ALERE, INC
  • FIG. 26: BUSINESS PERFORMANCE OF ABBOTT LABORATORIES
  • FIG. 27: BUSINESS PERFORMANCE OF DIASORIN
Back to Top